Paradigm Capital Management Inc. NY Invests $61.77 Million in Integra LifeSciences Holdings Corporation $IART

Paradigm Capital Management Inc. NY purchased a new position in shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 3,439,098 shares of the life sciences company’s stock, valued at approximately $61,766,000. Integra LifeSciences accounts for about 1.7% of Paradigm Capital Management Inc. NY’s investment portfolio, making the stock its 14th biggest holding.

Several other institutional investors and hedge funds have also modified their holdings of the business. Global Retirement Partners LLC bought a new stake in Integra LifeSciences during the 4th quarter worth approximately $25,000. Osaic Holdings Inc. lifted its stake in Integra LifeSciences by 36.6% in the second quarter. Osaic Holdings Inc. now owns 4,119 shares of the life sciences company’s stock valued at $51,000 after buying an additional 1,104 shares in the last quarter. Tower Research Capital LLC TRC boosted its holdings in shares of Integra LifeSciences by 595.6% in the second quarter. Tower Research Capital LLC TRC now owns 7,958 shares of the life sciences company’s stock valued at $98,000 after buying an additional 6,814 shares during the period. Virtu Financial LLC acquired a new position in shares of Integra LifeSciences in the fourth quarter valued at approximately $124,000. Finally, Sequoia Financial Advisors LLC increased its position in shares of Integra LifeSciences by 27.4% during the first quarter. Sequoia Financial Advisors LLC now owns 14,233 shares of the life sciences company’s stock worth $134,000 after acquiring an additional 3,059 shares in the last quarter. 84.78% of the stock is currently owned by institutional investors and hedge funds.

Integra LifeSciences Price Performance

Shares of IART opened at $16.69 on Tuesday. The company has a quick ratio of 2.11, a current ratio of 3.60 and a debt-to-equity ratio of 1.75. Integra LifeSciences Holdings Corporation has a twelve month low of $8.70 and a twelve month high of $20.49. The stock has a market capitalization of $1.30 billion, a P/E ratio of -185.42, a P/E/G ratio of 1.41 and a beta of 1.21. The company has a 50 day moving average of $17.98 and a 200-day moving average of $14.11.

Integra LifeSciences (NASDAQ:IART) last announced its quarterly earnings data on Wednesday, July 29th. The life sciences company reported $0.56 EPS for the quarter, topping analysts’ consensus estimates of $0.48 by $0.08. Integra LifeSciences had a negative net margin of 0.44% and a positive return on equity of 18.30%. The business had revenue of $418.76 million for the quarter, compared to analyst estimates of $417.54 million. Integra LifeSciences has set its Q3 2026 guidance at 0.530-0.610 EPS and its FY 2026 guidance at 2.400-2.500 EPS. As a group, equities research analysts forecast that Integra LifeSciences Holdings Corporation will post 2.46 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the stock. Wells Fargo & Company raised their price objective on shares of Integra LifeSciences from $15.00 to $18.00 and gave the stock an “equal weight” rating in a report on Thursday, July 30th. Argus raised shares of Integra LifeSciences from a “hold” rating to a “buy” rating and set a $25.00 target price for the company in a research note on Thursday, June 18th. Weiss Ratings upgraded Integra LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, August 14th. Citigroup reissued a “neutral” rating and issued a $19.00 price target (up from $16.00) on shares of Integra LifeSciences in a research note on Wednesday, July 8th. Finally, Wall Street Zen lowered Integra LifeSciences from a “strong-buy” rating to a “buy” rating in a report on Saturday, July 18th. One investment analyst has rated the stock with a Buy rating, five have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Reduce” and an average price target of $18.86.

About Integra LifeSciences

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.